Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

The tumour suppressor CDKN2A/p16 INK4a regulates adipogenesis and bone marrow-dependent development of perivascular adipose tissue.

Wouters K., Deleye Y., Hannou SA., Vanhoutte J., Maréchal X., Coisne A.

Animal Study on Type 2 Diabetes, published in Diab Vasc Dis Res (2017) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Diab Vasc Dis Res (2017)
Country
England
Reported sample size
—
Source database
PubMed
PMID
28868898
DOI
10.1177/1479164117728012

Abstract (original English)

The genomic CDKN2A/B locus, encoding p16 INK4a among others, is linked to an increased risk for cardiovascular disease and type 2 diabetes. Obesity is a risk factor for both cardiovascular disease and type 2 diabetes. p16 INK4a is a cell cycle regulator and tumour suppressor. Whether it plays a role in adipose tissue formation is unknown. p16 INK4a knock-down in 3T3/L1 preadipocytes or p16 INK4a deficiency in mouse embryonic fibroblasts enhanced adipogenesis, suggesting a role for p16 INK4a in adipose tissue formation. p16 INK4a -deficient mice developed more epicardial adipose tissue in response to the adipogenic peroxisome proliferator activated receptor gamma agonist rosiglitazone. Additionally, adipose tissue around the aorta from p16 INK4a -deficient mice displayed enhanced rosiglitazone-induced gene expression of adipogenic markers and stem cell antigen, a marker of bone marrow-derived precursor cells. Mice transplanted with p16 INK4a -deficient bone marrow had more epicardial adipose tissue compared to controls when fed a high-fat diet. In humans, p16 INK4a gene expression was enriched in epicardial adipose tissue compared to other adipose tissue depots. Moreover, epicardial adipose tissue from obese humans displayed increased expression of stem cell antigen compared to lean controls, supporting a bone marrow origin of epicardial adipose tissue. These results show that p

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
3T3-L1 CellsAdipocytesAdipogenesisAdipose TissueAdiposityAdultAgedAnimalsBone MarrowBone Marrow Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research